Home

Charles Evan Ballantyne

CIK 1371742 · Chief Financial Officer · last filed 2023-04-12

Charles Evan Ballantyne is a Chief Financial Officer who has filed 16 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for GANX, was dated Apr 12, 2023. Across all open-market trades the lifetime net is +$130.3K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $11.1K across reported positions. 6 SEC filings were submitted jointly with AGENUS INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$11.1K

Companies

4

Total Filings

16

Lifetime Open-Market Net

$130.3K

Filer Profile

Reported Address
27 HEARTHSTONE ROAD
HOPKINTON, MA 01748
Related Filers
AGENUS INC — 6 joint filings, latest 2016-06-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GANX Chief Financial Officer — $1.75 — $0 1 2023-04-12
AGEN CFO 1,595 $6.94 $11.1K $50.5K 5 2016-06-16
Theriva Biologics, Inc. (SYN) Delisted Chief Financial Officer — $1.02 — $0 1 2015-01-12
CLINICAL DATA INC (CLDA) Delisted EVP, CFO 0 — — $79.8K 9 2011-04-14

Recent Filings

16 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-04-12 GANX Grant (A) — $0 EDGAR
2016-06-16 AGEN Grant (A) — $0 EDGAR
2016-05-13 AGEN Mixed +14,795 $61.4K EDGAR
2016-04-28 AGEN Mixed +14,648 $60.8K EDGAR
2015-09-29 AGEN Buy (P) +10,000 $50.5K EDGAR
2015-06-17 AGEN Grant (A) — $0 EDGAR
2015-01-12 Theriva Biologics, Inc. (SYN) Delisted Grant (A) — $0 EDGAR
2011-04-14 CLINICAL DATA INC (CLDA) Delisted Mixed −5,600 -$168.0K EDGAR
2010-12-23 CLINICAL DATA INC (CLDA) Delisted Grant (A) — $0 EDGAR
2009-12-22 CLINICAL DATA INC (CLDA) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 16
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.